Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Jiangsu Jibeier Pharmaceutical Co., Ltd. specializes in the development and manufacturing of generic and specialty pharmaceuticals, particularly in the therapeutic areas of oncology and cardiovascular diseases. Its competitive position is bolstered by a robust pipeline of products and a strong presence in the Chinese market, with exports to various international markets.
Jiangsu Jibeier generates revenue primarily through the sale of generic medications, leveraging its cost-effective manufacturing processes and strong distribution networks. The company benefits from pricing power due to its established brand reputation and regulatory approvals, which provide a competitive edge in the market.
Regulatory approvals for new drug applications
Changes in pricing policies for generic drugs in China
Market expansion efforts in Southeast Asia
Partnerships or collaborations with larger pharmaceutical companies
Regulatory changes impacting drug approval processes
Technological disruption in drug manufacturing
Increased competition from domestic and international generic manufacturers
Potential price erosion due to market saturation
Limited liquidity risk due to high current ratio of 9.35
Potential future capital needs for R&D investments
moderate - The pharmaceutical sector is somewhat insulated from economic downturns, but demand can be affected by consumer spending and healthcare budgets.
Low - The company has no debt, so rising interest rates do not impact financing costs. However, they could affect overall market valuations.
minimal - The company operates with a debt/equity ratio of 0.00, indicating no reliance on credit.
growth - Investors are likely attracted to the company's potential for revenue expansion through new product launches and market penetration.
moderate - Historical volatility is moderate, reflecting the stability of the pharmaceutical sector.